Prosthesis (i.e. – artificial body members) – parts thereof – or ai – Heart valve – Having rigid or semirigid pivoting occluder
Patent
1995-05-16
1998-02-24
Willse, David H.
Prosthesis (i.e., artificial body members), parts thereof, or ai
Heart valve
Having rigid or semirigid pivoting occluder
A61F 224
Patent
active
057207771
ABSTRACT:
Disclosed is a controlled autolysis method for making biological tissue substantially acellular by exposing the biological material, prior to any fixation thereof, to at least one buffered solution having a pH in the range from about 5.0 to 8.0 and a temperature in the range from about 12.degree. C. to 30.degree. C. for a sufficient period of time to render at least one region of the biological material substantially acellular while substantially preserving the structural integrity and non-cellular structural components of the biological material. Also disclosed is a method of making a bioprosthetic heart valve using biological material that has been treated by controlled autolysis and a method of treating a mammal having a defective heart valve using a bioprosthetic heart valve made, in part, by controlled autolysis.
REFERENCES:
patent: 4083066 (1978-04-01), Schmitz et al.
patent: 4120649 (1978-10-01), Schechter
patent: 4239492 (1980-12-01), Holman et al.
patent: 4323358 (1982-04-01), Lentz et al.
patent: 4378224 (1983-03-01), Nimni et al.
patent: 4383832 (1983-05-01), Fraefel et al.
patent: 4402697 (1983-09-01), Pollock et al.
patent: 4405327 (1983-09-01), Pollock
patent: 4553974 (1985-11-01), Dewanjee
patent: 4647283 (1987-03-01), Carpentier et al.
patent: 4648881 (1987-03-01), Carpentier et al.
patent: 4704131 (1987-11-01), Noishiki et al.
patent: 4729139 (1988-03-01), Nashef
patent: 4770665 (1988-09-01), Nashef
patent: 4776853 (1988-10-01), Klement et al.
patent: 4786287 (1988-11-01), Nashef et al.
patent: 4798611 (1989-01-01), Freeman, Jr.
patent: 4800603 (1989-01-01), Jaffe
patent: 4801299 (1989-11-01), Brendel et al.
patent: 4838888 (1989-06-01), Nashef
patent: 4885005 (1989-12-01), Nashef et al.
patent: 4976733 (1990-12-01), Girardot
patent: 4996054 (1991-02-01), Pietsch et al.
patent: 5002566 (1991-03-01), Carpentier et al.
patent: 5094661 (1992-03-01), Levy et al.
patent: 5104405 (1992-04-01), Nimni
patent: 5145771 (1992-09-01), Lemasters et al.
patent: 5192312 (1993-03-01), Orton
patent: 5215541 (1993-06-01), Nashef et al.
patent: 5336616 (1994-08-01), Livesay et al.
patent: 5397353 (1995-03-01), Oliver et al.
"Damage of Porcine Aortic Valve Tissue Caused by the Surfactant Sodiumdodecylsuphat,"Bodnar, et al., Thorac. Cardiovasc. Surgeon. vol. 32, pp., 82-85, 1986.
"Degeneration and Calcification of Bioprosthetic Cardiac Valves," Bioprosthetic Tricuspid Valve Implantation in Sheep.
Barnhart, et al., Animal Model of Human Diseases, pp. 136-139.
"Techniques for Prevention of Calcification of Valvular Bioprostheses," Carpentier, et al., Valvular Heart Disease Circulation vol. 70 (Suppl I), 1984.
"Possible Causes for the Calcification of Glutaraldehyde-Treated Tissue Heart Valves and Blkiood Contacting Elastomers During Prolonged Use in Medical Devices: A Physicochemical View ," S.D. Bruck. Biomaterials. vol. 2, 1981.
"Treatment of Tissues or Organs (e.g. pig heart valves) Used for Animal or Human Transplant," Glick et al., Derwent Publications Ltd., 1988, one page.
"Calcific Deposits in Porcine Bioprostheses: Structure and Pathogenesis," Ferrans et al., The American Journal of Cardiology, vol. 46, 1980.
"The Cryopreserved Homograft Valve in the Pulmonary Position: Mid-Term Results and Technical Consideration," Lamberti, et al., Journal of Cardiac Surgery, vol. 6, No. 4, Supplement, pp. 627-632, 1991.
"Aortic Valve Allografts for Mitral Valve Replacement," Stinson, et al., Surgery, vol. 77, No. 6, pp. 861-867, Jun. 1975.
"Calcification of Glutaraldehyde-Preserved Porcine Xenografts in Young Patients," Curcio et al., J. Thorac. Cardiovasc. Surgery. vol. 81, pp. 621-625, 1981.
"Calcification of Glutaraldehyde-Preserved Porcine and Bovin Xenograft valves in Young Children," Fiddler et al., The Annals of Thoratice Surgery, vol. 35, No. 3, pp. 257-261 Mar. 1983.
"A Study of the Cells in the Explanted Viable Cyropreserved Allograft Valve," O'Brien et al., Journal of Cardiac Surgery, vol. 3, pp. 279-287, Supplement, 1988.
"Calcific Stenosis of the Porcine Heterograft," Lamberti et al., The Annals of Thoracic Surgery, vol. 28, No. 1, pp. 28-32, 1979.
"Calcification in Procine Xenograft Valves in Children,"Silver et al., The American Journal of Cardiology, vol. 45, pp. 685-689, Mar. 1980.
"Calcification of Porcine Prosthetic Heart valves: A Radiographic and Light Microscopic Study," Cipriano et al., Circulation, vol. 66, No. 5, pp. 1100-1104 , Nov. 1982.
"Marked Thrombosis and Calcification of Porcine Heterograft Valves," Platt et al., Circulation, vol. 62, No. 4, pp. 862-869, Oct. 1980.
"Durability of the Viable Aortic Allograft," Angell et al., J. Thorac. Cardiovasc. Surg., vol. 98, pp. 48-56, 1989.
Hancock Warren D.
Jaffe Norman
Hancock Jaffee Laboratories
Willse David H.
LandOfFree
Biological material pre-fixation treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biological material pre-fixation treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biological material pre-fixation treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1872351